Skip to content
Screener

Alumis Inc. ALMS Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Amgen logo
AmgenAMGN
$95.64B+8.8%
Immunome logo
ImmunomeIMNM
$565.38M+90.8%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$504.48M+33.8%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$490.78M+288%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$363.79M-30.1%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.52B+693%
Enterprise value$3.49B+955%
P/S418.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
(in thousands, except share and per share amounts)March 31, 2026December 31, 2025
Preferred stock, $0.0001 par value; 50,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, voting, $0.0001 par value; 492,815,092 voting shares authorized as of March 31, 2026 and December 31, 2025; 123,169,838 and 99,084,365 voting shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively129
Common stock, non-voting, $0.0001 par value; 7,184,908 non-voting shares authorized as of March 31, 2026 and December 31, 2025; 4,059,908 and 5,622,408 non-voting shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1
Additional paid-in capital1,562,4051,202,975
Accumulated other comprehensive income (loss)(467)188
Accumulated deficit(994,929)(901,876)
Total stockholders’ equity567,021301,297
Total liabilities and stockholders’ equity$671,588$411,940

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s total liabilities & equity?
Alumis Inc. (ALMS) reported total liabilities & equity of $671.59M in Q1 2026.
How has Alumis Inc.'s total liabilities & equity changed year-over-year?
Alumis Inc.'s total liabilities & equity increased by 157.0% year-over-year, from $261.3M to $671.59M.
What is the long-term trend for Alumis Inc.'s total liabilities & equity?
Over 2 years (2023 to 2025), Alumis Inc.'s total liabilities & equity has grown at a 114.4% compound annual growth rate (CAGR), from $89.61M to $411.94M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Alumis Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude